Know Labs, Seattle-based company that provides diagnostic solutions, developed a small device that uses artificial intelligence to identify blood alcohol levels non-invasively. The Bio-RFID™ platform technology is more accurate than the conventional devices that monitor blood alcohol levels, according to the company. The device can also detect blood glucose.
“Not only can we detect the holy grail of biotech, blood glucose, but also blood alcohol and more will come in the future,” says Phil Bosua, CEO of Know Labs.
Know Labs just released a video of the device, Bosua not only discusses the Company’s use of Bio-RFID to detect blood alcohol levels, but the broad implications for its technology platform.
“Over the last month we’ve been powering through a ton of experiments and innovations and are really happy to report we’ve now got an AI based algorithm that allows our technology to detect blood alcohol levels non-invasively. So, it’s official – Bio-RFID is now a platform technology. Not only can we detect the holy grail of biotech – blood glucose – but also – blood alcohol, and more to come in the future,” says Bosua.
“You’re witnessing a technology emerge that will change personal medicine forever. And we have even bigger plans for this that we hope will transform early warning medical diagnosis.”
Know Labs’ technology directs structured light or radio waves through a substance or material to capture a unique molecular signature. The Company refers to these signatures as ChromaID™ and Bio-RFID™. ChromaID and Bio-RFID are used to identify, detect, or diagnose substance markers or biomarkers that may be invisible to the human eye. ChromaID and Bio-RFID scanner modules can be integrated into a variety of wearable, mobile or bench-top form factors. This patented and patent pending, award-winning technology makes it possible to effectively conduct analyses that could only previously be performed by invasive and/or large and expensive lab-based tests.